Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd Asset Resilience Ratio
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd asset resilience ratio. Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (600671) has an Asset Resilience Ratio of 0.81% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Hangzhou TianMuShan Pharmaceutical Enter liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (1993–2011)
Asset resilience ratio of Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd from 1993 to 2011. This chart shows how Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's Asset Resilience Ratio has changed over time. Read total liabilities of Hangzhou TianMuShan Pharmaceutical Enter for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Hangzhou TianMuShan Pharmaceutical Enter.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥3.50 Million | 0.81% |
| Total Liquid Assets | CN¥3.50 Million | 0.81% |
Asset Resilience Insights
- Limited Liquidity: Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd maintains only 0.81% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd Industry Peers by Asset Resilience Ratio
Compare Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 0.08% |
|
AstraZeneca PLC
NASDAQ:AZN |
Drug Manufacturers - General | 0.10% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.33% |
|
Novartis AG
MX:NVSN |
Drug Manufacturers - General | 0.08% |
|
Biogen Inc
NASDAQ:BIIB |
Drug Manufacturers - General | 0.00% |
|
Organon & Co
NYSE:OGN |
Drug Manufacturers - General | 4.46% |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019 |
Drug Manufacturers - General | 0.53% |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771 |
Drug Manufacturers - General | 1.97% |
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd Asset Resilience Ratio by Year (1993–2011)
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd asset resilience ratio by year from 1993 to 2011. The table below shows the annual Asset Resilience Ratio data for Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2011-12-31 | 0.31% | CN¥1.12 Million ≈ $164.07K |
CN¥357.84 Million ≈ $52.36 Million |
+0.23pp |
| 2010-12-31 | 0.08% | CN¥253.08K ≈ $37.03K |
CN¥319.79 Million ≈ $46.80 Million |
+0.07pp |
| 2009-12-31 | 0.00% | CN¥16.29K ≈ $2.38K |
CN¥328.27 Million ≈ $48.04 Million |
-0.01pp |
| 2008-12-31 | 0.02% | CN¥68.44K ≈ $10.01K |
CN¥369.08 Million ≈ $54.01 Million |
-1.99pp |
| 2007-12-31 | 2.01% | CN¥8.33 Million ≈ $1.22 Million |
CN¥414.09 Million ≈ $60.59 Million |
+1.99pp |
| 2005-12-31 | 0.03% | CN¥95.01K ≈ $13.90K |
CN¥372.71 Million ≈ $54.54 Million |
0.00pp |
| 2004-12-31 | 0.03% | CN¥94.19K ≈ $13.78K |
CN¥357.85 Million ≈ $52.37 Million |
-8.14pp |
| 2001-12-31 | 8.17% | CN¥33.40 Million ≈ $4.89 Million |
CN¥408.75 Million ≈ $59.81 Million |
-0.29pp |
| 2000-12-31 | 8.46% | CN¥34.34 Million ≈ $5.03 Million |
CN¥405.88 Million ≈ $59.39 Million |
+3.02pp |
| 1999-12-31 | 5.44% | CN¥18.50 Million ≈ $2.71 Million |
CN¥339.78 Million ≈ $49.72 Million |
-1.32pp |
| 1997-12-31 | 6.76% | CN¥20.00 Million ≈ $2.93 Million |
CN¥295.69 Million ≈ $43.27 Million |
-2.66pp |
| 1996-12-31 | 9.43% | CN¥24.45 Million ≈ $3.58 Million |
CN¥259.33 Million ≈ $37.95 Million |
-14.31pp |
| 1995-12-31 | 23.73% | CN¥62.43 Million ≈ $9.13 Million |
CN¥263.02 Million ≈ $38.49 Million |
+7.77pp |
| 1994-12-31 | 15.96% | CN¥30.66 Million ≈ $4.49 Million |
CN¥192.12 Million ≈ $28.11 Million |
+1.82pp |
| 1993-12-31 | 14.15% | CN¥16.06 Million ≈ $2.35 Million |
CN¥113.50 Million ≈ $16.61 Million |
-- |
About Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd, together with its subsidiaries, engages in the pharmaceutical manufacturing and drug distribution businesses in China. The company produces tablets, granules, pills, oral solutions, and other medications; and health food products, including oral liquids, syrups, eye drops, pills, soft capsules, tablets, and granules. It also sells prepared sl… Read more